Publications

2015

Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, et al. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget. 2015;6(7):4863-87.
Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson S-, et al. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015;13(10):1431-40.
Linares JF, Duran A, Reina-Campos M, Aza-Blanc P, Campos A, Moscat J, et al. Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade. Cell Rep. 2015;12(8):1339-52.
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844-52.
Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, et al. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015;36(6):639-47.
Weidner A-, Molina D, DeSimone RA, Cohen MA, Giorgadze T, Scognamiglio T, et al. Riedel thyroiditis: Fine needle aspiration findings of a rare entity. Diagn Cytopathol. 2015;43(9):747-50.
Cho H, Herzka T, Stahlhut C, Watrud K, Robinson BD, Trotman LC. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome. Methods. 2015;77-78:197-204.
Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015;1(4):466-74.
Zhao X, Chen-Kiang S, Shetty S, Di Liberto M, Bodo J, Durkin L, et al. CCMCL1: a new model of aggressive mantle cell lymphoma. Blood. 2015;125(17):2730-2.
Mitchell CJ, Getnet D, Kim M-, Manda SS, Kumar P, Huang T-, et al. A multi-omic analysis of human naïve CD4+ T cells. BMC Syst Biol. 2015;9:75.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700